Syncromune

Fort Lauderdale, United States

Syncromune is a clinical stage biopharmaceutical dedicated to the development of better immunotherapies for metastatic solid tumors.

$100.0M raised

Dec 2024

Series A

Top Investors

Wasatch Equity Partners

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Syncromune raised?

Syncromune has raised $100.0M in total funding. The most recent round was Series A. The last funding was announced in December 2024.

Who are Syncromune's investors?

Syncromune's investors include Wasatch Equity Partners.

Where is Syncromune headquartered?

Syncromune is headquartered in Fort Lauderdale, United States.

What does Syncromune do?

Syncromune is a clinical stage biopharmaceutical dedicated to the development of better immunotherapies for metastatic solid tumors.

What stage is Syncromune at?

Syncromune is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated December 20, 2024.

MLA

"Syncromune — Funding & Investors." VCBacked, December 20, 2024, https://www.vcbacked.co/company/syncromune. Accessed June 17, 2026.

APA

VCBacked. (2024). Syncromune — Funding & Investors. Retrieved June 17, 2026, from https://www.vcbacked.co/company/syncromune

Wikipedia (cite web)

{{cite web |title=Syncromune — Funding & Investors |url=https://www.vcbacked.co/company/syncromune |website=VCBacked |access-date=June 17, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated December 20, 2024.